Compare American Airlines Group Inc (AAL) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? American Airlines Group Inc trades at $14.97 (market cap $10.55B), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.8× American Airlines Group Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AAL | ALNY | |
|---|---|---|
Market Cap | $10.55B | $29.60B |
Sector | Industrials | Health |
52-Week High | $18.15 | $491.22 |
52-Week Low | $10.18 | $205.48 |
Enterprise Value | $38.51B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $14.94, down 0.43% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth but negative net income margin (-0.56%) and elevated P/E of 43.73. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.03 expected, while Q4 2025 missed estimates. Cash flow remains positive with $154M net cash flow in 2025. Analyst consensus is mixed with 44.7% buy ratings and $19.63 price target, representing 31% upside.
AAL presents a turnaround opportunity with premium revenue growth and debt reduction, but faces significant headwinds from fuel costs and negative equity. The stock trades below analyst targets but requires sustained profitability improvement to justify current valuation multiples. Key risks include fuel price volatility and competitive pressure in the airline industry.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
